News Study finds bebtelovimab therapy lacks efficacy in patients infected with SARS-CoV-2 Omicron subvariants By December 13, 202226 views ShareTweet 0 Researchers assessed the impact of bebtelovimab (BEB) monoclonal antibody in the treatment of high-risk SARS-CoV-2 Omicron variant-infected patients.
Comments